NuTide:701

NuCana (NCNA) presented data at ESMO 2025 demonstrating synergistic effects of NUC-7738 with PD-1 inhibitors in patient-derived organoids from renal cell carcinoma patients, enhancing tumor cell killing. These findings align with the Phase 1/2 NuTide:701 study, showing a favorable safety profile and tumor reduction in PD-1 refractory melanoma. Regulators approved a study expansion to enroll 28 more patients. NuCana plans to meet with the FDA to discuss a potential registration strategy for NUC-7738.